Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Almirall, I. Bolibar, M. Serra, E. Palomera, J. Roig, I. Hospital, E. Carandell, M. Agustí, P. Ayuso, A. Estela, M. De la Torre, A. Torres (Mataró, Barcelona, Valls, Palma de Mallorca, Tàrrega, Valencia, Maó, Spain; Escaldes-Engordany, Andorra). Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010; 36: Suppl. 54, 4960

Member's Comments

No comment yet.

Related content which might interest you: Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Risk factors of paediatric community-acquired pneumonia Source: Eur Respir J 2011; 37: 724-725 Year: 2011 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Risk factors of community-acquired pneumonia in children Source: Eur Respir J 2010; 36: 1221-1222 Year: 2010 Risk factors for pulmonary tuberculosis in community-acquired pneumonia Source: Eur Respir J 2014; 43: 1214 Year: 2014 Risk factors for pulmonary tuberculosis in community-acquired pneumonia Source: Eur Respir J 2014; 43: 1213 Year: 2014 Treatment failure of community-acquired pneumonia: risk factors and consequences Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Affecting factors of mortality in severe community-acquired pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 643s Year: 2005 Nebulised colistin for ventilator-associated pneumonia prevention Source: Eur Respir J 2015; 46: 1732-1739 Year: 2015 Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Biomarkers and cardiovascular events in community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008